Hansoh Pharmaceutical Group (HKG:3692) subsidiaries Shanghai Hansoh Biomedical and Jiangsu Hansoh Pharmaceutical Group signed a global license deal for their diabetes and weight loss drug candidate, HS-10535, according to Hong Kong bourse filing Wednesday.
A Merck Sharp & Dohme subsidiary will pay up to $2 billion to acquire the global license to develop, manufacture, and commercialize HS-10535, which includes a $112 million upfront payment and up to $1.9 billion in milestone payments, according to the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。